Why TerSera Therapeutics’ divestiture signals strategic realignment in niche infusion therapies and hospital medicines
ESTEVE acquires Prialt and Quzyttir from TerSera Therapeutics. Discover what this deal signals for non-opioid pain drugs and hospital specialty medicines.